

I hereby certify that this correspondence is being deposited with the United States Postal Service via facsimile to: Asst. Commissioner for Patents, ATTN: Examiner J. Stucker, Washington, D.C. 20231 at (703) 872-9306 on December 5, 2001.

By: *L. J. Dalton*

#8  
Amdt. R+  
Ecc.  
12/5/01

PATENT

Attorney Docket No. 015280-368200US

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re the application of:

Jay Berzofsky, et al.

Examiner: J. Stucker

Application No.: 09/508,552

Art Unit: 1648

Filed: June 12, 2000

For: MUCOSAL CYTOTOXIC T  
LYMPHOCYTE RESPONSES**RESPONSE TO RESTRICTION  
REQUIREMENT**Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

This is in response to the Restriction Requirement dated July 5, 2001. Please consider the following amendments and remarks prior to substantive examination of the present application.

**IN THE SPECIFICATION:**

Kindly replace the paragraph at page 5, line 34 to page 6, line 4, with the following paragraph:

Also provided within the invention are immunogenic compositions for inducing a protective mucosal CTL response in a subject which are adapted for intrarectal administration. The compositions comprise a purified soluble antigen formulated for intrarectal delivery to the rectum, colon, sigmoid colon, or distal colon. They may be formulated as a rectal enema, foam, suppository, or topical gel and generally comprise a base, carrier, or absorption-promoting agent adapted for intrarectal delivery.

SUB  
BI  
A